Published in Blood Weekly, September 21st, 2006
In a recent report, researchers in Japan conducted a study "to evaluate the expression of thymidylate synthase and dihydropyrimidine dehydrogenase in prostate tissue. Tissue from 79 patients with localized prostate cancer was used. Thymidylate synthase and dihydropyrimidine dehydrogenase expression were determined semiquantitatively by immunohistochemistry.
"Thymidylate synthase and dihydropyrimidine dehydrogenase immunostaining grades of benign tissue were significantly higher than those of cancer tissue (both p<0.01)."
"Cancer tissue with a primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.